Capricor Therapeutics Inc (CAPR)
6.05
-0.20
(-3.20%)
USD |
NASDAQ |
May 23, 16:00
6.05
0.00 (0.00%)
After-Hours: 20:00
Capricor Therapeutics SG&A Expense (Quarterly): 3.920M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 3.920M |
| December 31, 2023 | 2.987M |
| September 30, 2023 | 3.022M |
| June 30, 2023 | 2.847M |
| March 31, 2023 | 3.418M |
| December 31, 2022 | 2.682M |
| September 30, 2022 | 2.565M |
| June 30, 2022 | 2.357M |
| March 31, 2022 | 2.716M |
| December 31, 2021 | 2.116M |
| September 30, 2021 | 1.801M |
| June 30, 2021 | 1.79M |
| March 31, 2021 | 1.906M |
| December 31, 2020 | 1.493M |
| September 30, 2020 | 1.302M |
| June 30, 2020 | 1.610M |
| March 31, 2020 | 1.138M |
| December 31, 2019 | 0.8767M |
| September 30, 2019 | 0.912M |
| June 30, 2019 | 0.8319M |
| March 31, 2019 | 0.9765M |
| December 31, 2018 | 1.105M |
| September 30, 2018 | 1.259M |
| June 30, 2018 | 1.178M |
| March 31, 2018 | 1.390M |
| Date | Value |
|---|---|
| December 31, 2017 | 1.238M |
| September 30, 2017 | 1.089M |
| June 30, 2017 | 1.247M |
| March 31, 2017 | 1.189M |
| December 31, 2016 | 1.154M |
| September 30, 2016 | 1.260M |
| June 30, 2016 | 1.434M |
| March 31, 2016 | 1.085M |
| December 31, 2015 | 1.078M |
| September 30, 2015 | 0.9728M |
| June 30, 2015 | 0.9263M |
| March 31, 2015 | 1.396M |
| December 31, 2014 | 0.6847M |
| September 30, 2014 | 0.8197M |
| June 30, 2014 | 0.6657M |
| March 31, 2014 | 0.8523M |
| December 31, 2013 | 0.6778M |
| September 30, 2013 | 0.5639M |
| June 30, 2013 | 0.4928M |
| March 31, 2013 | 0.4744M |
| December 31, 2012 | 0.0254M |
| September 30, 2012 | 0.3972M |
| June 30, 2012 | |
| March 31, 2012 | 0.50M |
| December 31, 2011 | 0.5189M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.8319M
Minimum
Jun 2019
3.920M
Maximum
Mar 2024
2.114M
Average
2.011M
Median
SG&A Expense (Quarterly) Benchmarks
| Sarepta Therapeutics Inc | 127.00M |
| PTC Therapeutics Inc | 73.27M |
| Solid Biosciences Inc | 7.989M |
| Inovio Pharmaceuticals Inc | 10.57M |
| Stereotaxis Inc | 6.469M |